Please see Vox & Proactive interviews following the release of today’s RNS:
https://twitter.com/PoolbegPharma/status/1714175552251142252
https://www.voxmarkets.co.uk/articles/jeremy-skillington-of-poolbeg-pharma-discusses-their-nasdaq-partnership-for-development-581b7af/
#POLB signed a strategic collaboration agreement with a #Nasdaq listed #biopharma to develop an optimised #oraldrug for a metabolic condition using #POLB's licensed technology
They are optimistic that this can lead to a full licensing agreement!!
https://www.londonstockexchange.com/news-article/POLB/poolbeg-partners-with-a-nasdaq-listed-biopharma/16169180
“…I am taking 90 per cent of my remuneration in shares. We think the price of the shares are particularly distressed and we want to get in the trenches with the shareholders…”
https://total-market-solutions.com/2023/10/ecr-minerals-oct-2023/
“…Further exploration is underway, funded by the fresh revenue channels opened this summer. Production at the pilot plant continues to ramp up. And an off-take agreement may be not too far down the road…”
https://total-market-solutions.com/2023/10/andrada-mining-ltd/
“…Nevada is the top place in the world to explore and develop. Golden Metal Resources hosts the largest known, undeveloped, tungsten resource in the US. With tungsten on the US’s critical minerals list there’s grants out there for explorers…”
https://total-market-solutions.com/2023/10/golden-metal-resources-plc-october/
Poolbeg Pharma specialises in the development of innovative medicines to address the unmet need in infectious and other prevalent diseases. Poolbeg has a disciplined portfolio approach to mitigate risk, accelerate drug development, and enhance investor returns. The Company simultaneously advances multiple programmes in cost-effective clinical trials, rapidly generating early human safety and efficacy data to enable early partnering / out-licensing, with the funds generated reinvested in the pipeline. Poolbeg also uses AI to interrogate human challenge trial data sets to quickly identify new targets and drugs, and in-license near or in the clinic medicines, leading to faster development and greater commercial appeal. The Company is targeting the growing infectious disease market. In the wake of the COVID-19 pandemic, infectious disease has become one of the fastest growing pharma markets and is expected to exceed $250bn by 2025. Through opportunistic identification of assets which complement Poolbeg's existing pipeline, the Company is progressing programmes in oncology and metabolic syndromes; adding disease areas with significant addressable markets. With its initial assets from hVIVO plc (formerly Open Orphan plc), an industry leading infectious disease and human challenge trials business, Poolbeg has access to knowledge, experience, and clinical data from over 20 years of human challenge trials. The Company is using these insights to acquire new assets as well as reposition clinical stage products, reducing spend and risk. Amongst its portfolio of exciting assets, Poolbeg has a small molecule immunomodulator for severe influenza and other acute inflammatory conditions (POLB 001) which produces a highly significant reduction in p38 MAP kinase driven cytokines in a clinical setting; a first-in-class, intranasally administered RNA-based immunotherapy for respiratory virus infections (POLB 002); and a vaccine candidate for Melioidosis (POLB 003). The Company is also developing two Oral Delivery Programmes and is progressing two Artificial Intelligence (AI) Programmes to add promising new assets to its pipeline.
Https://twitter.com/PoolbegPharma/status/1711260201095983330
Insightful article on how #AI can help to speed up #drugdiscovery.
The high quality & unique nature of human challenge trial data can power AI-enabled #drugdiscovery to identify novel & unlock meaningful insights into human disease
https://www.nature.com/articles/d41586-023-02896-9
Pneumagen have announced the positive challenge trial results for their broad-spectrum antiviral candidate Neumifil. This is fantastic news for #HVO as it is yet another example of the value of the human challenge trials in delivering clinical efficacy data and de-risking later clinical development.
Human challenge have immense potential for growth among biotech companies, as the cost‐effective human efficacy data generated by human challenge trials becomes increasingly appealing in a tight funding environment. Positive efficacy data can significantly boost the value of an asset, which can be transformative for biotechs. Additionally, challenge trial data can accelerate time‐to‐market for vaccines and antivirals by up to three years, enabling biopharma companies to maximise revenues for their products whilst their patents are active.
Link to RNS below :
https://polaris.brighterir.com/public/hvivo/news/rns/story/wkj1qor
An interview featuring Jeremy Skillington and Emily Liu, following her industry piece on AI:
https://www.youtube.com/watch?v=TWl5aCf-seo
“…With cash in hand, a new venture in a growing market, and an ambitious management team that has proven its ability to identify and develop a growth business, LETS seems an intriguing prospect – especially with a share price of just 2.65p and a market cap of £5m. With a seasonal product likely to generate a Q4 revenues boost, LETS promises to be a microcap worth watching over the coming months…”
https://total-market-solutions.com/2023/10/lets-explore-group-plc/
...hVIVO shared a Sky News article on rising HMPV cases in Australia:
https://twitter.com/hVIVO_UK/status/1708763649622282704
HVO have a Human Challenge Model for hMPV of course...
https://hvivo.com/human-challenge-models/hmpv/
“Significant strategic interest in our assets”
https://www.youtube.com/watch?v=cgIt_T6SJ08
“…hoped we would already be able to announce the rig contract for NJOM-3 by the end of this quarter, however, we are currently at a 𝐯𝐞𝐫𝐲 𝐚𝐝𝐯𝐚𝐧𝐜𝐞𝐝 stage of negotiations on the rig contract and so we hope this will be concluded soon…”
https://www.londonstockexchange.com/news-article/TRP/interim-results-to-30-june-2023/16145203
The European Patent Office has decided against proceeding with the scheduled hearing relating to the opposition to the Company’s Immunomodulator I European patent. This follows the withdrawal of the patent opposition by a third party as announced on 19 September 2023. This favourably concludes this matter with the patent maintained as granted.
https://www.londonstockexchange.com/news-article/POLB/favourable-conclusion-of-patent-opposition/16145276
“…Battle-hardened with money in the bank and a clear plan, prospective investors should take the time to understand the company’s multi-tiered strategy, and be prepared to hold as the value of its assets are gradually unlocked, together – hopefully for all of the #BLOE stakeholders – with the value of its shares…”
https://total-market-solutions.com/2023/09/block-energy-plc-6/
Poolbeg Pharma PLC7.2p
Target Price: 19.0
Ticker: POLB
Poolbeg Pharma specialises in the development of innovative medicines to address the unmet need in infectious and other prevalent diseases. Poolbeg has a disciplined portfolio approach to mitigate risk, accelerate drug development, and enhance investor returns. The Company simultaneously advances multiple programmes in cost-effective clinical trials, rapidly generating early human safety and efficacy data to enable early partnering / out-licensing, with the funds generated reinvested in the pipeline. Poolbeg also uses AI to interrogate human challenge trial data sets to quickly identify new targets and drugs, and in-license near or in the clinic medicines, leading to faster development and greater commercial appeal. The Company is targeting the growing infectious disease market. In the wake of the COVID-19 pandemic, infectious disease has become one of the fastest growing pharma markets and is expected to exceed $250bn by 2025. Through opportunistic identification of assets which complement Poolbeg's existing pipeline, the Company is progressing programmes in oncology and metabolic syndromes; adding disease areas with significant addressable markets. With its initial assets from hVIVO plc (formerly Open Orphan plc), an industry leading infectious disease and human challenge trials business, Poolbeg has access to knowledge, experience, and clinical data from over 20 years of human challenge trials. The Company is using these insights to acquire new assets as well as reposition clinical stage products, reducing spend and risk. Amongst its portfolio of exciting assets, Poolbeg has a small molecule immunomodulator for severe influenza and other acute inflammatory conditions (POLB 001) which produces a highly significant reduction in p38 MAP kinase driven cytokines in a clinical setting; a first-in-class, intranasally administered RNA-based immunotherapy for respiratory virus infections (POLB 002); and a vaccine candidate for Melioidosis (POLB 003). The Company is also developing two Oral Delivery Programmes and is progressing two Artificial Intelligence (AI) Programmes to add promising new assets to its pipeline.
The #POLB CEO will be presenting at the @DDWJournal webinar on 10 October 2023
AI and Lab Automation: What are the key benefits and latest innovations?
Register here:
https://www.ddw-online.com/webinar-key-benefits-and-latest-innovations-in-ai-and-lab-automation-25862-202309/